Back to top
more

IDEXX Laboratories (IDXX)

(Real Time Quote from BATS)

$626.22 USD

626.22
501,846

-15.72 (-2.45%)

Updated Aug 6, 2025 03:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm

by Zacks Equity Research

Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.

    Zacks Equity Research

    Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm

    by Zacks Equity Research

    Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.

      Zacks Equity Research

      BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)

      by Zacks Equity Research

      BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

        Zacks Equity Research

        Phibro Animal (PAHC) Beats Q4 Earnings & Sales Estimates

        by Zacks Equity Research

        Phibro Animal (PAHC) reported solid fourth-quarter fiscal 2017 revenues on the back of sales growth in the Animal Health, Mineral Nutrition and Performance Products segments.

          Zacks Equity Research

          VWR Awaits Merger Closure, Stock Upside Potential Limited

          by Zacks Equity Research

          VWR Corporation's (VWR) $6.4 billion acquisition by Avantor should create a major consumables-focused solutions and services provider to lucrative life sciences and advanced technologies industries.

            Zacks Equity Research

            Cooper (COO) Poised to Grow on Specialty Lenses Prospects

            by Zacks Equity Research

            Cooper's (COO) strong sales growth will continue to be aided by its leading position in the markets of specialty lenses.

              Zacks Equity Research

              Thermo Fisher Acquires Patheon, Boosts Laboratory Products

              by Zacks Equity Research

              Thermo Fisher's (TMO) acquisition of Patheon significantly strengthens its Pharmaceutical and Biotech business by adding complementary services.

                Zacks Equity Research

                Here's Why You Should Buy Lantheus Holdings (LNTH) Right Now

                by Zacks Equity Research

                Lantheus Holdings (LNTH) banks on DEFINITY and TechneLite sales for growth. The company's focus on global expansion is also encouraging.

                  Zacks Equity Research

                  Intuitive Surgical (ISRG) Well Poised on Procedural Business

                  by Zacks Equity Research

                  Intuitive Surgical's (ISRG) strong sales growth will continue to be aided by focus on da Vinci system and procedural growth from general surgery, oncology, urology and gynecology.

                    Zacks Equity Research

                    LabCorp Grows on Solid Diagnostics, Currency Woes a Drag

                    by Zacks Equity Research

                    Although LabCorp's (LH) Covance drug development business puts up a dull performance, the market is upbeat about its Diagnostics business, which has recently displayed a solid show.

                      Zacks Equity Research

                      Medtronic (MDT) Sees a Mixed Q1, New Products Bode Well

                      by Zacks Equity Research

                      Despite mixed results in Q1, Medtronic (MDT) displayed balanced growth with strength in three of its major business segments.

                        Zacks Equity Research

                        PetMed Express Focuses on Advertising, Competition Rife

                        by Zacks Equity Research

                        PetMed Express (PETS) focuses on advertising to boost new order sales is striving to implement several strategies to revitalize its top line.

                          Zacks Equity Research

                          Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm

                          by Zacks Equity Research

                          Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.

                            Zacks Equity Research

                            LabCorp & Interpace Extend Deal, Boost Cancer Portfolio

                            by Zacks Equity Research

                            LabCorp's (LH) agreement to offer Interpace Diagnostics' molecular tests, ThyGenX and ThyraMIR gets renewed and extended for another two years.

                              Zacks Equity Research

                              NxStage System One Gets FDA Nod for Solo Home Hemodialysis

                              by Zacks Equity Research

                              The latest regulatory go-ahead is likely to lend NxStage (NXTM) a competitive edge and expand its patient base with solid access to the clinical benefits associated with home hemodialysis.

                                Zacks Equity Research

                                Veeva (VEEV) to Gain Through Subscription Revenue Focus

                                by Zacks Equity Research

                                Veeva's (VEEV) strong sales growth will continue to be aided by focus on subscription revenue, better pricing and product innovation. However, higher costs remain a concern.

                                  Zacks Equity Research

                                  Hill-Rom (HRC) Stock Down With Dull Patient Support Systems

                                  by Zacks Equity Research

                                  Hill-Rom's (HRC) Patient Support Systems revenue decreases due to the adverse effect of the WatchChild and Architectural Products divestitures along with lower rental revenues.

                                    Zacks Equity Research

                                    LabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval

                                    by Zacks Equity Research

                                    The Federal Trade Commission (FTC) has granted LabCorp's (LH) request for an early closure of Chiltern's acquisition under HSR Act.

                                      Zacks Equity Research

                                      Express Scripts to Boost Oral Medication With Diabetes Study

                                      by Zacks Equity Research

                                      Express Scripts' (ESRX) new study will support oral diabetes medication and reduce related costs.

                                        Zacks Equity Research

                                        IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why

                                        by Zacks Equity Research

                                        Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.

                                          Zacks Equity Research

                                          Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength

                                          by Zacks Equity Research

                                          Luminex (LMNX) has a broad range of products that are built on advanced technology. Also, it has collaborative agreements with several companies, which should help expand the use of its products.

                                            Zacks Equity Research

                                            Chemed (CHE) on Growth Track With VITAS & Roto-Rooter Arms

                                            by Zacks Equity Research

                                            The raised outlook for both Roto-Rooter unit and the bottom line indicate Chemed's (CHE) estimate of improved operating results in the upcoming quarters.

                                              Zacks Equity Research

                                              Illumina Teams Up With Telegraph Hill to Form Verogen

                                              by Zacks Equity Research

                                              Illumina (ILMC) and Telegraph Hill Partners plan to set up Verogen to accelerate adoption of NGS in the global forensic genomics market.

                                                Zacks Equity Research

                                                Veeva Systems (VEEV) Beats Q2 Earnings, Revenue Estimates

                                                by Zacks Equity Research

                                                Veeva Systems (VEEV) witnessed stellar numbers in the second quarter owing to strong adoption of products like Veeva Network, Veeva Align, Veeva OpenData and Veeva CRM Approved Email.

                                                  Zacks Equity Research

                                                  Align Technology-Patterson Dental Deal Expands iTero Reach

                                                  by Zacks Equity Research

                                                  Align Technology (ALGN) progresses with a slew of developments in the scanners and services segment.